Key result
GLP-1RA linked to ~34% lower mortality vs SGLT2i in anthracycline-treated breast cancer patients with diabetes.
Why the study?
Anthracyclines cause cardiotoxicity and downstream morbidity in breast cancer, but whether GLP-1RA and SGLT2i influence outcomes beyond cardio-renal endpoints in diabetic women receiving anthracyclines remained unknown.
Do GLP-1RA and SGLT2i improve cardio-renal and other clinical outcomes in anthracycline-treated women with breast cancer and diabetes?
Cohort
Yes
Do GLP-1RA and SGLT2i improve cardio-renal and other clinical outcomes in anthracycline-treated women with breast cancer and diabetes?
In diabetic women with breast cancer treated with anthracyclines, GLP-1RA and SGLT2i are associated with improved survival and fewer complications, with GLP-1RA showing superior cardio-renal protection compared to SGLT2i.
Answers are grounded in this paper and cite their sources.
May warrant GLP-1RA/SGLT2i consideration in diabetic anthracycline recipients; leaves open confirmation via RCTs for cardio-renal and other events.
e23079 Background: Anthracyclines remain central to breast cancer therapy but are associated with cardiotoxicity and downstream morbidity. In women with diabetes mellitus, GLP-1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter-2 inhibitors (SGLT2i) may influence outcomes beyond cardio-renal endpoints. We evaluated clinically relevant events (cytopenias, infections, venous thromboembolism, polyneuropathy, mood disorders) in addition to cardio-renal outcomes in anthracycline-treated women with breast cancer and diabetes. Methods: Using the TriNetX Global Collaborative Network, we identified women ≥18 years with breast cancer, diabetes mellitus, and anthracycline exposure. Three 1:1 propensity-matched comparisons were performed: (1) SGLT2i without GLP-1RA vs neither exposure (n = 934/arm), (2) GLP-1RA without SGLT2i vs neither exposure (n = 982/arm), and (3) GLP-1RA vs SGLT2i (n = 703/arm). Matching included demographics, cardiometabolic comorbidities, antihyperglycemic medications, and cancer therapies along with radiation therapy. Outcomes were assessed through 3 years post-index using time-to-event analyses; HRs with 95% CIs are reported. Results: Versus neither exposure, SGLT2i was associated with lower hazard of severe cytopenias (Hb < 8 g/dL, neutropenia and platelets < 50,000/µL), sepsis (0.615, 0.478 - 0.792), neutropenic fever (0.419, 0.283 - 0.622), VTE (DVT: 0.673, 0.468 - 0.967; PE: 0.603, 0.414 - 0.878), polyneuropathy (0.822, 0.687 - 0.984) and mood disorders (0.743, 0.608 - 0.907). GLP-1RA exposure versus neither exposure was associated with lower cytopenias, sepsis (0.553, 0.423 - 0.724), neutropenic fever (0.419, 0.283 - 0.622), and VTE outcomes (DVT: 0.654, 0.468 - 0.914; PE: 0.449, 0.307 - 0.655). In head-to-head analyses, GLP-1RA demonstrated lower hazard of heart failure (0.505, 0.389 - 0.656), cardiomyopathy (0.396, 0.273 - 0.574), AKI (0.704, 0.531 - 0.934), hospital visits (0.862, 0.752 - 0.989), and mortality (0.663, 0.486 - 0.905), while most cytopenia/infection and VTE outcomes were similar with either therapy. Polyneuropathy and mood disorder diagnoses were higher with GLP-1RA versus SGLT2i (1.272, 1.052 - 1.539; 1.241, 1.008 - 1.528). CKD and stroke were not significantly different with either therapy. Conclusions: In this propensity-matched real-world cohort of anthracycline-treated women with breast cancer and diabetes, both GLP-1RA and SGLT2i were associated with improved survival and fewer cytopenias, infections, and VTE versus no exposure. Compared with SGLT2i, GLP-1RA showed more favorable cardio-renal and survival outcomes, whereas SGLT2i was associated with fewer polyneuropathy and mood disorder diagnoses. Prospective validation is needed.
No takes yet. Share an insight, caveat, or question.
Sood et al. (2026) conducted a cohort in Breast cancer and diabetes mellitus with anthracycline exposure. GLP-1RA and SGLT2i vs. Neither exposure or each other was evaluated on Mortality (GLP-1RA vs SGLT2i) (HR 0.663, 95% CI 0.486-0.905). GLP-1RA was associated with lower mortality compared to SGLT2i in anthracycline-treated women with breast cancer and diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: